GENLISA™ SARS-CoV-2 (Covid-19) Beta Neutralizing Antibody (B.1.351, B.1.351.2,B.1.351.3) ELISA

0 - 2000 ng/ml

Colorimetric, 450nm

ELISA for the Quantitative determination of neutralizing antibody to the SARS-CoV-2 receptor binding domain (RBD) of Beta variant (South Africa variant) in serum and plasma samples. One of the WHO?s variants of concern, the beta coronavirus strain more than 8?mutations in the spike protein, as well as several other mutations in other locations. Existing vaccines were moderately effective against the variant. As other Krishgen ELISA, these kits are based on monoclonal antibody detection for better sensitivity. A sandwich ELISA design and specific antibodies allow for a robust ELISA. Features include a standard, ready-to-use protocol, and the option to run serum or plasma samples. Detecting and quantifying neutralizing antibodies to SARS-CoV-2 offers important information in the evaluation of immune responses, development of vaccines and therapeutic drugs. The kit employs a blocking ELISA technique which mimics the virus neutralization process. Potent neutralizing antibodies often target the receptor interaction site in S1, disabling receptor interactions. The spike proteins of SARS-CoV-2 commonly bind to the human angiotensin converting enzyme 2 (ACE2) protein as a host receptor through their S1B domain. Receptor interaction is known to trigger irreversible conformational changes in coronavirus spike proteins enabling membrane fusion. SARS-CoV-2 initiates an immune response, which leads to the production of antibodies. These neutralizing antibodies disable host receptor interactions and prevent viral entry into the cell. They, therefore, also provide protection against future infection from SARS-CoV-2, as they remain in the circulatory system for months to years post infection.

Serum and Plasma

7.5 ng/ml